

Efficacy of Topical and Oral Anti-fungals in Pivotal Studies at the Genus and Species Level



Generic Name	Brand Name	FDA Indications	Course of Therapy	Complete Cure (%) Treatment	Mycologic Cure (%) Treatment
Ciclopirox ^{1,3}	Penlac®	<i>Trichophyton rubrum</i>	1/day, 48 weeks	5.5-8.5	29-36
Efinaconazole ^{1,4}	Jublia®	<i>Trichophyton rubrum</i> , <i>Trichophyton mentagrophytes</i>	1/day, 48 weeks	15.2-17.8	53.4-55.2
Tavaborole ^{1,5}	Kerydin®	<i>Trichophyton rubrum</i> , <i>Trichophyton mentagrophytes</i>	1/day, 48 weeks	6.5-9.1	31.1-35.9
Itraconazole ⁶	Sporanox®	Capsules: For the treatment of onychomycosis of the toenail due to dermatophytes (<i>tinea unguium</i>) in non-immunocompromised patients	1/day, 12 weeks	14	54
Terbinafine ^{7,8}	Lamisil®	Treatment of onychomycosis of the toenail due to dermatophytes (<i>tinea unguium</i>)	1/day, 12 weeks	38	70
Griseofulvin ⁹	Grifulvin V® Gris-PEG®	<i>Trichophyton rubrum</i> , <i>Trichophyton mentagrophytes</i> + 9 more dermatophytes	1/day, 6 months (adult)	46	54
Fluconazole ¹⁰	Diflucan®	<i>Candida</i> (not FDA indicated for the treatment of onychomycosis)	1/week, 6 months	61	69

REFERENCES

- Gupta AK et al. Improving Cure Rates in Onychomycosis. J Cutan Med Surg. 2016 Nov;20(6):517-531. Epub 2016 Jun 16.
- Zaug M. Amorolfine nail lacquer: clinical experience in onychomycosis. J Eur Acad Dermatol Venereol. 1995;4:523-530.
- Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol. 2000;43(4)(suppl):S70-S80.
- Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solu-tion in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68(4):600-608.
- Elewski BE, Aly R, Baldwin SL, et al. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifun-gal agent, for the treatment of toenail onychomycosis: results from 2 randomized phase-III studies. J Am Acad Dermatol. 2015;73(1):62-69.
- Sporanox (itraconazole) [package insert]. Titusville, NJ: Janssen Pharmaceuticals Inc. 2012.
- Supplement to Podiatry Today® November 2013
- Lamisil (terbinafine HCl) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp. 2012.
- Grifulvin V, Gris-PEG (Griseofulvin) [package insert]Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807 USA
- Diflucan (Fluconazole) [package insert] Roerig, Division of Pfizer Inc., NY, NY 10017

TRADEMARKS

PENLAC is a trademark of Hoechst Marion Roussel, Inc.
 JUBLIA, GRIFULVIN V, GRIS-PEG trademark of Valeant Pharmaceuticals Ireland Limited
 KERYDIN trademark of Anacor Pharmaceuticals, Inc.
 SPORANOX trademark of Johnson & Johnson
 LAMISIL trademark of Novartis AG
 DIFLUCAN trademark by Pfizer Inc.